Division of Plastic Surgery, The Thomas E. Starzl Transplantation Institute, University of Pittsburgh WBST1557, 200 Lothrop Street, Pittsburgh, PA 15213, United States.
Cytokine. 2010 Sep;51(3):311-9. doi: 10.1016/j.cyto.2010.06.007. Epub 2010 Jul 2.
It has been reported that Th1 to Th2 immune deviation effectively promotes peripheral tolerance in situations involving a limited T cell clone size, such as T cell-dependent autoimmunity and transplantation across minor, but not major, histocompatibility barriers. In this study, we tested the hypothesis that while Th1 to Th2 immune deviation fails to induce tolerance in the MHC-mismatched islet allograft model, it may promote a state that is permissive for tolerance induction. Here, we report that anti-IL-12 did not prevent acute rejection of islet allografts when administered alone. In conjunction with CTLA4/Fc, however, anti-IL-12 greatly facilitated long-term engraftment in three MHC-mismatched strain combinations. Similarly, while non-cytolytic IL-4/Fc, a long-lasting form of IL-4, did not prevent acute graft rejection when administered alone, a low, but not a high, dose of IL-4/Fc synergized with CTLA4/Fc in inducing significant levels of islet allograft tolerance. Moreover, by using a skin allograft adoptive transfer model, we show that these effects induced by anti-IL-12 and IL-4/Fc treatment were associated with an enhancement of the suppressive properties of CD4(+)CD25(+) regulatory T cells. Thus, anti-IL-12 and low-dose IL-4/Fc facilitate, but do not cause, islet allograft tolerance in mice by increasing the immunosuppressive potency of CD4(+)CD25(+) regulatory T cells.
据报道,Th1 向 Th2 免疫偏离有效地促进了外周耐受,这种情况涉及有限的 T 细胞克隆大小,如 T 细胞依赖性自身免疫和跨越次要但不是主要组织相容性障碍的移植。在这项研究中,我们检验了这样一个假设,即在 MHC 错配胰岛同种异体移植物模型中,Th1 向 Th2 免疫偏离不能诱导耐受,但它可能促进一种允许诱导耐受的状态。在这里,我们报告抗 IL-12 单独给药时不能预防胰岛同种异体移植物的急性排斥。然而,与 CTLA4/Fc 联合使用时,抗 IL-12 极大地促进了三种 MHC 错配品系组合中的长期移植物植入。同样,虽然非细胞溶解 IL-4/Fc,一种长效的 IL-4,单独给药时不能预防急性移植物排斥,但低剂量而不是高剂量的 IL-4/Fc 与 CTLA4/Fc 协同诱导显著水平的胰岛同种异体移植物耐受。此外,通过使用皮肤同种异体移植物过继转移模型,我们表明抗 IL-12 和 IL-4/Fc 治疗引起的这些效应与 CD4(+)CD25(+)调节性 T 细胞的抑制特性增强有关。因此,抗 IL-12 和低剂量 IL-4/Fc 通过增加 CD4(+)CD25(+)调节性 T 细胞的免疫抑制效力,促进但不会导致小鼠胰岛同种异体移植物耐受。